Generate Biomedicines, founded by Flagship Pioneering, uses generative AI to design entirely new protein therapeutics across modalities, advancing a pipeline of AI-generated drug candidates.
Biotech📍 Somerville, MAFounded 2018
Current Valuation
Private
PRIVATE
QL Price
$2.2B
0% vs last round
QuantLogix's current estimate for Generate Biomedicines, published 2026-09-21 — in line with the last disclosed round of $2.2B (2026-02).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$2.2B
2026-02
weight 0.64
Secondary market print
$2.2B
2026-06-27
weight 0.6
How this price has held up
No round has priced for Generate Biomedicines since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-21 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Generate Biomedicines, 2026-09-21 (bcdda63e54630974).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Generate Biomedicines going public?
No. Generate Biomedicines is private and has not filed to go public. There is no S-1 on file.
What is Generate Biomedicines' valuation in 2026?
No confirmed valuation is on record for Generate Biomedicines. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Generate Biomedicines filed an S-1?
No public S-1 is on file for Generate Biomedicines.
Can you buy Generate Biomedicines stock?
No. Generate Biomedicines is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Generate Biomedicines on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Mike Nally
Founded
2018
HQ
Somerville, MA
IPO Status
private
Fundraising Status
private
Secondary Market
Implied price / share
$5.75
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Name-verified against lead sponsor "Generate Biomedicines" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
14
via greenhouse
Product-build share
43%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 43% builders vs 57% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Director, Clinical Scientist (Respiratory indications)Principal Workday Engineer (HRIS)Scientist I / Scientist II, Computational Protein DesignSenior Director, Medical Monitor (Respiratory indications)Senior Machine Learning Scientist I/II, Model-Driven OptimizationSenior Scientist I, Biotherapeutic Production Technologies
Counted from Generate Biomedicines's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.